Novo Nordisk announced that the company will launch its diabetes treatment Ozempic, containing the active ingredient semaglutide, as a non-reimbursed drug starting on Thursday
January 29, 2025 At a Glance GLP-1 users likely need supplements to make up the calorie deficit they experience from the resulting weight loss
Patients taking medications with anticholinergic properties, benzodiazepines, opioids, or certain antihypertensives may experience cognitive effects from these agents
The current understanding, shaped largely by tirzepatide research, is more nuanced GIPR activation appears synergistic with GLP-1R activation in contexts where single-receptor work predicted a smaller signal
Injection anxiety affects up to 20% of individuals, often due to concerns over self-injection accuracy or needle phobia
The clinical trials started every participant at 0.25 mg for good reason